* Disseminated on behalf of ARMR Sciences Inc.
* For Accredited Investors Only. Offered pursuant to Rule 506(c). Reasonable steps to verify accreditation will be taken before any sale.
PAID ADVERTISEMENT – SPONSORED CONTENT
Artificial intelligence (AI) is helping transform medicine, finance, and logistics. But experts warn it could also be turned against us. With advanced modeling, AI can now generate chemical blueprints at a substantially faster rate than previously available processes. As a result, National security leaders and AI thought leaders (including OpenAI’s Sam Altman), have voiced concerns that adversaries could weaponize AI to design new bioweapons.
The New Threat Landscape
Fentanyl already stands as the deadliest synthetic opioid in U.S. history, responsible for more than 220 deaths every day. But fentanyl itself is only the beginning.
Analogs like carfentanil (100x stronger), xylazine (non-opioid threat), and nitazenes (40x stronger) are beginning to spread, many of which are not reversible with Narcan.
The drug supply is becoming a testing ground for increasingly lethal compounds, some of which could be accelerated by AI-driven chemistry.
This dual challenge – lethal analogs on the street and the potential for AI-designed agents – has led federal agencies, including the Department of Defense and Homeland Security, to classify fentanyl and its cousins as chemical weapons of mass destruction.
The crisis is no longer just a health issue; it is a national security emergency.
ARMR’s Defense Labs Approach
ARMR Sciences is working to position itself to confront this next phase. Its Defense Labs initiative combines AI-powered drug discovery with seven years of Department of Defense–funded science with the goal of building a scalable biodefense platform.
The company’s lead candidate, ARMR-100, designed to train the immune system to block fentanyl before it reaches the brain. In preclinical (animal) studies, ARMR-100 blocked 92% of fentanyl’s entry into the brain and eliminated its addictive behavioral effects (at this stage ARMR-100 is not FDA-approved, human safety and efficacy have not been established, and preclinical results may not predict clinical outcomes).
Unlike reactive tools such as naloxone, ARMR-100 is designed to provide months of protection – a biochemical shield against fentanyl and, eventually, other engineered analogs.
Beyond fentanyl, ARMR plans to develop additional immunotherapies for xylazine, nitazenes, and other emerging threats, creating a portfolio that evolves alongside the risks.
By leveraging AI in its own labs, ARMR seeks to stay ahead of adversaries who might misuse the same technology. And in the battle between innovation and misuse, its proactive biodefense may prove to be America’s strongest shield.
The Scale and the Urgency
With more than 130 million people in the U.S. considered high-risk – from opioid use disorder patients to first responders and military personnel – the potential market is vast.
For policymakers, the message is clear: synthetic opioids are no longer only a health crisis, but a recognized national security threat. Classified alongside terrorism and cyberwarfare, fentanyl and its analogs demand rapid action.
This urgency is creating bipartisan momentum for federal funding, regulatory fast-tracking, and stockpiling of new countermeasures.
Why Investors Should Pay Attention
For investors, we believe that ARMR represents an opportunity to back a company that combines social impact with growth potential. Its model combines biotechnology, AI, and biodefense – a convergence few companies are addressing:
- Seven years of DoD-backed research formed the platform’s foundation
- Lead candidate ARMR-100 blocked 92% of fentanyl from entering the brain in preclinical studies
- A $30M private raise is now open
- A targeted exchange listing in the future
By investing in this round, investors have a chance to support ARMR as it works to build a category-defining role in AI-powered biodefense.
* For Accredited Investors Only. This offering is made pursuant to Rule 506(c) of Regulation D. All purchasers must be accredited investors, and the issuer will take reasonable steps to verify accredited status before any sale. Investing involves high risk, including the potential loss of your entire investment.
* This is a paid advertisement for ARMR’s private offering. Please read the details of the offering at InvestARMR.com for additional information on the company and the risk factors related to the offering.
* For investors from Canada: This advertisement forms part of the issuer’s marketing materials and is incorporated by reference into the issuer’s Offering Memorandum/Private Placement Memorandum under NI 45-106. Investors must receive and review the OM/PPM and execute the prescribed Form 45-106F4 Risk Acknowledgement before subscribing.
DISCLOSURES & DISCLAIMERS
CLIENT CONTENT: Carboncredits.com is not responsible for any content hosted on ARMR Sciences’ sites; it is ARMR Sciences’ responsibility to ensure compliance with applicable laws.
NOT INVESTMENT ADVICE: Content is for educational, informational, and advertising purposes only and should NOT be construed as securities-related offers or solicitations. All content should be considered promotional and subject to disclosed conflicts of interest.
Do NOT rely on this as personalized investment advice. Do your own due diligence.
Carboncredits.com strongly recommends you consult a licensed or registered professional before making any investment decision.
REGULATORY STATUS: Neither Carboncredits.com nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.
CONTENT & COMPENSATION DISCLOSURE: Carboncredits.com has received compensation of thirty thousand dollars from ARMR Sciences for this sponsored content. You should assume we receive compensation as indicated for any purchases through links in this email via affiliate relationships, direct/indirect payments from companies or third parties who may own stock in or have other interests in promoted companies. We may purchase, sell, or hold long or short positions without notice in securities mentioned in this communication.
RESULTS NOT TYPICAL: Past performance and results are unverified and NOT indicative of future results. Results presented are NOT guaranteed as TYPICAL. Market conditions and individual circumstances vary significantly. Actual results will vary widely. Investing in securities is speculative and carries high risk; you may lose some, all, or possibly more than your original investment.
HIGH-RISK: Securities discussed may be highly speculative investments subject to extreme volatility, limited liquidity, and potential total loss. The Securities are suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops, it may not continue.
DISCLAIMERS & CAUTIONARY STATEMENT: Certain statements in this presentation (the “Presentation”) may be deemed to be “forward-looking statements” within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor provisions for forward-looking statements. Such forward-looking statements can be identified by the use of words such as ”should,” ”may,” ”intends,” ”anticipates,” ”believes,” ”estimates,” ”projects,” ”forecasts,” ”expects,” ”plans,” and ”proposes.” Forward-looking statements, which are based on the current plans, forecasts and expectations of management of ARMR Sciences Inc. (the “Company” or “ARMR Sciences”), are inherently less reliable than historical information. Forward-looking statements are subject to risks and uncertainties, including events and circumstances that may be outside our control.
Although management believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. Risks and uncertainties that could cause actual results to differ materially include, without limitation, those risks identified in the Private Placement Memorandum. Forward-looking statements speak only as of the date of the document in which they are contained, and ARMR Sciences Inc. does not undertake any duty to update any forward-looking statements except as may be required by law.
Any forward-looking financial forecasts contained in this Presentation are subject to a number of risks and uncertainties, and actual results may differ materially. You are cautioned not to place undue reliance on such forecasts. No assurances can be given that the future results indicated, whether expressed or implied, will be achieved. While sometimes presented with numerical specificity, all such forecasts are based upon a variety of assumptions that may not be realized, and which are highly variable. Because of the number and range of the assumptions underlying any such forecasts, many of which are subject to significant uncertainties and contingencies that are beyond the reasonable control of the issuing company, many of the assumptions inevitably will not materialize and unanticipated events and circumstances may occur subsequent to the date of any financial forecast.
ARMR Sciences Inc. takes no responsibility for any forecasts contained within the Presentation. None of the information contained in any offering materials should be regarded as a representation by ARMR Sciences Inc. The Company’s forecasts have not been prepared with a view toward public disclosure or compliance with the guidelines of the SEC, the American Institute of Certified Public Accountants or the Public Company Accounting Oversight Board. Independent public accountants have not examined nor compiled any forecasts and have not expressed an opinion or assurance with respect to the figures.
This Presentation also contains estimates and other statistical data made by independent parties and by management relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.
ARMR Sciences Inc. is currently undertaking a private placement offering of Offered Shares pursuant to Section 4(a)(2) of the 1933 Act and/or Rule 506(c) of Regulation D promulgated thereunder. Investors should consider the investment objectives, risks, and investment time horizon of the Company carefully before investing. The private placement memorandum relating to the offering of Securities will contain this and other information concerning the Company, including risk factors, which should be read carefully before investing.
The Securities are being offered and sold in reliance on exemptions from registration under the 1933 Act. In accordance therewith, you should be aware that (i) the Securities may be sold only to “accredited investors,” as defined in Rule 501 of Regulation D; (ii) the Securities will only be offered in reliance on an exemption from the registration requirements of the Securities Act and will not be required to comply with specific disclosure requirements that apply to registration under the Securities Act; (iii) the United States Securities and Exchange Commission (the “SEC”) will not pass upon the merits of or give its approval to the terms of the Securities or the offering, or the accuracy or completeness of any offering materials; (iv) the Securities will be subject to legal restrictions on transfer and resale and investors should not assume they will be able to resell their securities; and (v) investing in these Securities involves a high degree of risk, and investors should be able to bear the loss of their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time.
The Company is “Testing the Waters” under Regulation A under the Securities Act of 1933. The Company is not under any obligation to make an offering under Regulation A. No money or other consideration is being solicited in connection with the information provided, and if sent in response, will not be accepted. No offer to buy the securities can be accepted and no part of the purchase price can be received until an offering statement on Form 1-A has been filed and until the offering statement is qualified pursuant to Regulation A of the Securities Act of 1933, as amended, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of its acceptance given after the qualification date.
The securities offered using Regulation A are highly speculative and involve significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue. The Company intends to list its securities on a national exchange and doing so entails significant ongoing corporate obligations including but not limited to disclosure, filing and notification requirements, as well compliance with applicable continued quantitative and qualitative listing standards.
